Spanish public debt to pharma suppliers in hospital medicines market at lowest level since 2006

8 February 2016
spain-big-1

The Spanish Autonomous Regions’ debt on payments for medicine supplied to the National Health hospitals dropped by around 30% with regards to the previous month.

Payments made by the Regions’ Financing Fund through the Autonomous Liquidity Fund (FLA) and the Finance Facility Fund, have established the debt to be around 2.20 billion euros ($2.4 billion) at the end of 2015; this is the most likely forecast, however is subject to  final consolidation.

Hence, all figures seem to indicate that 2015 closed its fiscal year with 13% less debt in the public hospital medicines market compared to 2014, which accounts for the best results seen since 2006 when debt sat at 2.14 billion euros, fixing the current figure in parameters that haven’t been registered since before the crisis.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical